Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,701,051.96 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 434,478 shares of the company’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the completion of the sale, the chief operating officer now owns 1,127,290 shares of the company’s stock, valued at $12,197,277.80. This represents a 27.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $10.67 on Wednesday. Roivant Sciences Ltd. has a 52 week low of $9.96 and a 52 week high of $13.06. The stock has a market capitalization of $7.61 billion, a P/E ratio of -71.13 and a beta of 1.26. The stock has a fifty day moving average of $10.78 and a 200-day moving average of $11.44.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities research analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

ROIV has been the topic of a number of analyst reports. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $17.10.

Institutional Trading of Roivant Sciences

Several institutional investors and hedge funds have recently made changes to their positions in ROIV. Nordea Investment Management AB increased its holdings in Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after purchasing an additional 52,031 shares during the last quarter. TOMS Capital Investment Management LP acquired a new position in Roivant Sciences during the third quarter valued at approximately $46,333,000. Barclays PLC increased its stake in Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after purchasing an additional 75,609 shares in the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock worth $45,147,000 after purchasing an additional 458,601 shares in the last quarter. Finally, Retirement Systems of Alabama increased its position in shares of Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after buying an additional 112,286 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.